Search results 1-3 of 3 in Gastrointestinal Disorders
Results
-
Rochester, Minn.
View Summary
Comparison of Diaphragmatic Breathing and Muscle Relaxation for Rumination
Location:
Rochester, Minn.
Trial status:
Open for Enrollment
Why is this study being done?
Rumination is an upper gastrointestinal (GI) disorder characterized by the frequent regurgitation of recently ingested food. Very little is understood about the nature and treatment of this disorder. The act of regurgitation in rumination involves the opening of the upper esophageal sphincter and the muscular contraction of the abdomins rectus. Behavioral treatment of these symptoms is the clinical intervention of choice; however, only uncontrolled case documentation exists to support its effectiveness. However, an effective behavioral mechanism may be relaxation of the muscles. From a behavioral standpoint, muscular relaxation is incompatible with the necessary muscular contraction for rumination.
To date, single case documentation and few designed single case studies have examined the clinical effectiveness of behavioral interventions for GI rumination. In the current study, the investigators seek to examine the effectiveness of two behavioral relaxation interventions for GI rumination through a treatment as usual paradigm (proposed N = 20). Our primary goals are to examine the clinical effectiveness of these interventions in symptom reduction at 1- and 3-month follow-up.
NCT ID:
NCT01576302
IRB Number:
11-008528
Who can I contact for additional information about this study?
Rochester: Richard J Seime, Ph.D 507-284-2649
Jennifer M. Craft, Ph.D. 507 284 5849
-
Rochester, Minn.
View Summary
Trial of Montelukast in Eosinophilic Esophagitis
Location:
Rochester, Minn.
Trial status:
Open for Enrollment
Why is this study being done?
We will randomize in a double blind manner 60 consecutive consenting patients being evaluated at the three Mayo Clinic Medical Centers with EE to montelukast 20mg daily or placebo daily for six months? time. Patients will be in remission after treatment with topical fluticasone therapy before enrollment. Patients will fill out a validated dysphagia and side effect questionnaire before, during, and at the end of therapy.
NCT ID:
NCT00511316
IRB Number:
06-003373
Who can I contact for additional information about this study?
Rochester: Debra M. Geno, CCRP 507-538-0367
-
Rochester, Minn.
View Summary
A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
Location:
Rochester, Minn.
Trial status:
Open for Enrollment
Why is this study being done?
This study is being done to see if Lyrica helps people with irritable bowel syndrome, otherwise known as "IBS". Lyrica is the trade name for pregabalin, which was first approved by the FDA in June 2005 and has been available through prescription since fall 2005, and is marketed by Pfizer. Lyrica is known to have clinical efficacy treating pain disorders including IBS-related conditions such as fibromyalgia.
NCT ID:
NCT00977197
IRB Number:
09-004404
Who can I contact for additional information about this study?
Rochester: Annie Almazar 507-284-5010